This section of the website is for UK public only

If you are a UK Healthcare Professional please click here.

If you are a UK patient please click here.

OPDIVO (nivolumab)

OPDIVO is a medication that has the following indications:

  • as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults - a form of skin cancer which is not suitable for surgery

  • for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults - types of lung cancer which have spread near the lungs or to other parts of the body

  • as monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults - a form of kidney cancer that has spread across the body

OPDIVO is a type of immunotherapy which means it works by boosting the immune system's ability to detect and fight disease.

Visit MacMillan Cancer Support for further information about melanoma ,non-small cell lung cancer or,renal cell carcinoma. You can also find out further information from your Healthcare Professional.

1506UK1600992-01
Date of preparation: May 2016

Contact us Legal Notice
Privacy policy Patient information leaflet

Reporting of side effects and additional monitoring

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

1506UK1600144-08
Date of preparation: March 2016